Insider Selling: Relay Therapeutics (NASDAQ:RLAY) Insider Sells 8,530 Shares of Stock

Key Points

• Relay Therapeutics insider Donald Bergstrom sold 8,530 shares at an average price of $18.97, generating $161,814.10 and reducing his ownership by 2.09%.
• RLAY shares fell 2.4% to $18.66, while the company’s latest quarterly results missed expectations, reporting a $0.41-per-share loss and $0.35 million in revenue.
• Analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating and a $25.92 price target; institutional investors own 96.98% of the stock.

Relay Therapeutics, Inc. (NASDAQ:RLAY - Get Free Report) insider Donald Bergstrom sold 8,530 shares of the company's stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $18.97, for a total value of $161,814.10. Following the sale, the insider owned 399,130 shares of the company's stock, valued at $7,571,496.10. The trade was a 2.09% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Relay Therapeutics Trading Down 2.4%

NASDAQ RLAY traded down $0.45 during trading on Wednesday, hitting $18.66. 5,942,384 shares of the company's stock were exchanged, compared to its average volume of 3,175,174. The company has a market cap of $4.09 billion, a PE ratio of -11.89 and a beta of 1.69. The stock's 50 day moving average price is $19.35 and its two-hundred day moving average price is $15.27. Relay Therapeutics, Inc. has a fifty-two week low of $3.87 and a fifty-two week high of $21.27.

Relay Therapeutics (NASDAQ:RLAY - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.39) by ($0.02). The company had revenue of $0.35 million for the quarter, compared to analyst estimates of $0.96 million. Analysts forecast that Relay Therapeutics, Inc. will post -1.61 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Relay Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of RLAY. Tidal Investments LLC raised its position in shares of Relay Therapeutics by 14.7% during the 2nd quarter. Tidal Investments LLC now owns 176,782 shares of the company's stock valued at $3,308,000 after buying an additional 22,682 shares in the last quarter. Integrated Wealth Concepts LLC purchased a new position in Relay Therapeutics in the second quarter worth $74,000. Allianz Asset Management GmbH purchased a new position in Relay Therapeutics in the second quarter worth $750,000. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in Relay Therapeutics in the second quarter valued at $784,000. Finally, California State Teachers Retirement System raised its position in Relay Therapeutics by 1,726.3% during the second quarter. California State Teachers Retirement System now owns 3,179,652 shares of the company's stock valued at $59,491,000 after purchasing an additional 3,005,553 shares in the last quarter. 96.98% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the company. Barclays increased their price target on Relay Therapeutics from $27.00 to $30.00 and gave the company an "overweight" rating in a research note on Friday, August 7th. Citizens Jmp lifted their target price on Relay Therapeutics from $21.00 to $26.00 and gave the company a "market outperform" rating in a research report on Monday, August 10th. Citigroup reiterated a "market outperform" rating on shares of Relay Therapeutics in a research note on Monday, August 10th. JonesTrading raised shares of Relay Therapeutics from a "hold" rating to a "strong-buy" rating in a report on Tuesday, May 19th. Finally, UBS Group set a $26.00 price target on Relay Therapeutics in a research report on Tuesday, May 19th. Two research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $25.92.

About Relay Therapeutics

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company's core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.